Publicado abr 5, 2022



PLUMX
Almetrics
 
Dimensions
 

Google Scholar
 
Search GoogleScholar


Catalina Rodriguez Prada https://orcid.org/0000-0001-6822-2214

Elkin Rene Barrios Peralta https://orcid.org/0000-0002-5985-0603

Gabriel Fernando Oviedo Lugo https://orcid.org/0000-0001-6119-7060

Rafael Gustavo Castellanos Garzón https://orcid.org/0000-0001-5078-880X

##plugins.themes.bootstrap3.article.details##

Resumen

La pasta de cocaína (PBC/basuco) es una droga ilícita consumida principalmente en los países de Latinoamérica que se encuentra combinada con otros productos químicos para lograr un costo menor en el mercado. Esto mismo hace que sea de más fácil acceso para muchas personas. El consumo del basuco produce efectos a corto y largo plazo sobre el organismo, la persona, la familia y la sociedad. En este artículo se exploran aspectos relacionados con la neurobiología de la adicción al basuco, el diagnóstico de la intoxicación y sus opciones terapéuticas.

Keywords

Cocaína; Trastornos relacionados a la cocaína; fumar cocaína; Trastornos Relacionados con Sustancias.

References

1. United Nations Office on Drugs and Crime. World drug report 2017. Washington: United Nations Publication; 2018.
2. Pascale A, Hynes M, Cumsille FB. Use of cocaine base paste in South America: a review of epidemiological, medical and toxicological issues. Washington: Organization of American States and Inter-American Drug Abuse Control Commission; 2014.
3. Castaño Pérez GA. Cocaínas fumables en Latinoamérica. Adicciones [internet]. 2000;12(4):541-51. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=4473945
4. Sabogal-Carmona JS, Urrego-Novoa JR. Composición química de muestras de bazuco incautado en Colombia primer semestre de 2010. Rev Salud Pública. 2012;14(6):1010-21.
5. Gobierno Nacional de la República de Colombia. Estudio nacional de consumo de sustancias psicoactivas en Colombia-2013. Bogotá; 2014.
6. Observatorio de Drogas Colombia. Reporte de drogas de Colombia 2016. 2.ª ed. Bogotá: Gobierno de Colombia; 2016.
7. Pérez Gómez A. Transiciones en el consumo de drogas en Colombia. Adicciones [internet]. 2009;21(1):81-88. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=2945410
8. United Nations Office on Drugs and Crime. World drug report. Washington D. C.: United Nations; 2016.
9. Zimmerman JL. Cocaine intoxication. Crit Care Clin. 2012;28(4):517-26.
10. Oficina de las Naciones Unidas contra la Droga y el Delito. Pasta básica de cocaína: cuatro décadas de historia, actualidad y desafíos [internet]. Lima; 2013. Disponible en: https://www.unodc.org/documents/peruandecuador/Publicaciones/Publicaciones2013/LIBRO_PBC.pdf
11. Jones RT. Pharmacokinetics of cocaine: considerations when assessing cocaine use by urinalysis. NIDA Res Monogr. 1997;175:221-34.
12. Cone EJ, Tsadik A, Oyler J, Darwin WD. Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit. 1998 Oct;20(5):556-60.
13. Huestis MA, Darwin WD, Shimomura E, Lalani SA, Trinidad D V., Jenkins AJ, et al. Cocaine and metabolites urinary excretion after controlled smoked administration. J Anal Toxicol. 2007;31(8):462-8.
14. Weis S, Büttner A. Neurotoxicology and drug-related disorders. Handb Clin Neurol. 2017;145:181-192. https://doi.org/10.1016/B978-0-12-802395-2.00014-6
15. Schmidt KT, Schroeder JP, Foster SL, Squires K, Smith BM, Pitts EG, et al. Norepinephrine regulates cocaine-primed reinstatement via α1-adrenergic receptors in the medial prefrontal cortex. Neuropharmacology. 2017 Jun;119:134-40.
16. Cadet JL, Bisagno V, Milroy CM. Neuropathology of substance use disorders. Acta Neuropathol. 2014;127(1):91-107.
17. Liaudet L, Calderari B, Pacher P. Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity. Heart Fail Rev. 2014 Nov;19(6):815-24.
18. Mersereau EJ, Poitra SL, Espinoza A, Crossley DA, Darland T. The effects of cocaine on heart rate and electrocardiogram in zebrafish (Danio rerio). Comp Biochem Physiol Part C Toxicol Pharmacol. 2015 Jun;172-173:1-6.
19. Manetti L, Cavagnini F, Martino E, Ambrogio A. Effects of cocaine on the hypothalamic-pituitary-adrenal axis. J Endocrinol Invest. 2014 Aug;37(8):701-8.
20. Miller BL, Mena I, Giombetti R, Villanueva-Meyer J, Djenderedjian AH. Neuropsychiatric effects of cocaine: SPECT measurements. J Addict Dis. 1992 Dec;11(4):47-58.
21. Yeoh JW, James MH, Jobling P, Bains JS, Graham BA, Dayas C V. Cocaine potentiates excitatory drive in the perifornical/lateral hypothalamus. J Physiol. 2012 Aug;590(16):3677-89.
22. Cavalcante JC, Cândido PL, Sita LV, do Nascimento ES, Cavalcante J de S, de Oliveira Costa MSM, et al. Comparative distribution of cocaine- and amphetamine-regulated transcript (CART) in the hypothalamus of the capuchin monkey (Cebus apella) and the common marmoset (Callithrix jacchus). Brain Res. 2011 Nov;1425:47-61.
23. Plósz BG, Reid MJ, Borup M, Langford KH, Thomas K V. Biotransformation kinetics and sorption of cocaine and its metabolites and the factors influencing their estimation in wastewater. Water Res. 2013 May;47(7):2129-40.
24. Dinis-Oliveira RJ. Metabolomics of cocaine: implications in toxicity. Toxicol Mech Methods. 2015;25(6):494-500.
25. Kudlacek O, Hofmaier T, Luf A, Mayer FP, Stockner T, Nagy C, et al. Cocaine adulteration. J Chem Neuroanat. 2017 Oct;83-84:75-81.
26. Yu J, Yan Y, Li K-L, Wang Y, Huang YH, Urban NN, et al. Nucleus accumbens feedforward inhibition circuit promotes cocaine self-administration. Proc Natl Acad Sci. 2017 Oct;114(41):E8750-9.
27. James MH, Mahler SV, Moorman DE, Aston-Jones G. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? Curr Top Behav Neurosci. 2017;33:247-281. https://doi.org/10.1007/7854_2016_57
28. Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest. 2012 Oct;122(10):3387-93.
29. Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 1988 Mar;244(3):1067-80.
30. Unterwald EM, Rubenfeld JM, Kreek MJ. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport. 1994 Aug;5(13):1613-6.
31. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 1996 Nov;2(11):1225-9.
32. Bobzean SAM, DeNobrega AK, Perrotti LI. Sex differences in the neurobiology of drug addiction. Exp Neurol. 2014 Sep;259:64-74.
33. Marrocco J, McEwen BS. Sex in the brain: hormones and sex differences. Dialogues Clin Neurosci. 2016;18(4):373-83.
34. Williams SK, Johns JM. Prenatal and gestational cocaine exposure: effects on the oxytocin system and social behavior with implications for addiction. Pharmacol Biochem Behav. 2014 Apr;119:10-21.
35. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction. 2000 Aug;95 Suppl 2:S91-117.
36. Noël X, Brevers D, Bechara A. A neurocognitive approach to understanding the neurobiology of addiction. Curr Opin Neurobiol. 2013 Aug;23(4):632-8.
37. Pierce RC, Fant B, Swinford-Jackson SE, Heller EA, Berrettini WH, Wimmer ME. Environmental, genetic and epigenetic contributions to cocaine addiction. Neuropsychopharmacology. 2018 Jun;43(7):1471-80.
38. Jonkman S, Kenny PJ. Molecular, cellular and structural mechanisms of cocaine addiction: a key role for microRNAs. Neuropsychopharmacology. 2013 Jan;38(1):198-211.
39. Schmidt HD, Pierce RC. Cocaine-induced neuroadaptations in glutamate transmission. Ann N Y Acad Sci. 2010 Feb;1187(1):35-75.
40. Llosa T. Smoking coca paste and crack-tobacco must be treated as double addiction. Subst Abus. 2009 Jan-Mar;30(1):81. https://doi.org/10.1080/08897070802606519
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5.ª ed. Washington D. C.; 2013.
42. Hernández-Vásquez A, Núñez S, Santero M, Grendas L, Huarez B, Vilcarromero S, et al. Risk factors associated with drug use before imprisonment in Peru. Rev Esp Sanid Penit. 2018;20(1):11-20.
43. Cunha SM da, Araujo RB, Bizarro L. Profile and pattern of crack consumption among inpatients in a Brazilian psychiatric hospital. Trends Psychiatry Psychother. 2015 Sep;37(3):126-32.
44. Del Bosque J, Mairena AF, Díaz DB, Espínola M, García NG, Abdalá AL, et al. La cocaína: consumo y consecuencias. Salud Ment. 2014;37(5):381-9.
45. Yajaira D, Fernández B, Segura-Cardona Á, Montoya-Vélez L, Hernández-Rendón M. Consumo de basuco en usuarios de drogas inyectables en Colombia. Rev Cuba Salud Pública. 2016;42(2):276-83.
46. Yates WR, Fulton AI, Gabel JM, Brass CT. Personality risk factors for cocaine abuse. Am J Public Health. 1989 Jul;79(7):891-2.
47. Ospina-Díaz JM, Herrera-Amaya GM, Manrique-Abril FG. Illegal psychoactive substance consumption amongst older schoolchildren in the city of Tunja, Colombia. Rev Salud Pública (Bogotá). 2012 Jun;14(Supl 2):86-99. https://doi.org/10.1590/S0124-00642012000800008
48. Voon P, Ti L, Dong H, Milloy M-J, Wood E, Kerr T, et al. Risky and rushed public crack cocaine smoking: the potential for supervised inhalation facilities. BMC Public Health. 2016 Dec;16(1):476.
49. Lejuez CW, Bornovalova MA, Reynolds EK, Daughters SB, Curtin JJ. Risk factors in the relationship between gender and crack/cocaine. Exp Clin Psychopharmacol. 2007;15(2):165-75.
50. Touzé G, Rossi D, Vila M, Ralón G. VIH y el consumo de cocaína fumada/inhalada. En: Segunda Conferencia Latina sobre Reducción de Daños Virtual “Uso de drogas y salud pública: prevenir riesgos y reducir daños”. Porto: Grup IGIA-Universidade do Porto-Agência Piaget para o Desenvolvimento; 2008.
51. De Azevedo RCS, Botega NJ, Guimarães LAM. Crack users, sexual behavior and risk of HIV infection. Rev Bras Psiquiatr. 2007 Mar;29(1):26-30.
52. Digregorio GJ. Cocaina update: abuse and therapy. Am Fam Physician. 1990;41(1):247-50.
53. Navarro Cueva R, Yupanqui M. Perfiles del síndrome de la pasta básica de cocaína. Psicoactiva. 1988;2(1):55-90.
54. Pérez J. Clínica de la adicción a pasta base de cocaína. Rev Chil Neuro-Psiquiatr. 2003;41(1):55-63.
55. De Oliveira LG, Barroso LP, Silveira CM, Sanchez ZVDM, De Carvalho Ponce J, Vaz LJ, et al. Neuropsychological assessment of current and past crack cocaine users. Subst Use Misuse. 2009 Dec;44(13):1941-57.
56. Jones AW. Forensic drug profile: cocaethylene. J Anal Toxicol. 2019 Feb 23;43(3):155-60.
57. Lange RA, Cigarroa JE, Hillis LD. Theodore E. Woodward award: cardiovascular complications of cocaine abuse. Trans Am Clin Climatol Assoc. 2004;115:99-111; discussion 112-4.
58. Vasica G, Tennant CC. Cocaine use and cardiovascular complications. Med J Aust. 2002 Sep;177(5):260-2.
59. Om A. Cardiovascular complications of cocaine. Am J Med Sci. 1992 May;303(5):333-9.
60. Bigi MAB, Aslani A, Mehrpour M. Effect of chronic cocaine abuse on the elastic properties of aorta. Echocardiography. 2007 Oct;25(3):308-11.
61. Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad Med J. 2007 Jun;83(980):389-94.
62. Herculiani PP, Pires-Neto RC, Bueno HMS, Zorzetto JC, Silva LC, Santos ÁBG, et al. Effects of chronic exposure to crack cocaine on the respiratory tract of mice. Toxicol Pathol. 2009 Apr;37(3):324-32.
63. Pomara C, Cassano T, D’Errico S, Bello S, Romano AD, Riezzo I, et al. Data available on the extent of cocaine use and dependence: biochemistry, pharmacologic effects and global burden of disease of cocaine abusers. Curr Med Chem. 2012;19(33):5647-57.
64. Novick T, Liu Y, Alvanzo A, Zonderman AB, Evans MK, Crews DC. Lifetime cocaine and opiate use and chronic kidney disease. Am J Nephrol. 2016;44(6):447-53.
65. Goel N, Pullman JM, Coco M. Cocaine and kidney injury: a kaleidoscope of pathology. Clin Kidney J. 2014;7(6):513-7.
66. Carlin N, Nguyen N, DePasquale JR. Multiple gastrointestinal complications of crack cocaine abuse. Case Rep Med. 2014;2014:1-3.
67. Behnke M, Eyler FD, Garvan CW, Wobie K, Hou W. Cocaine exposure and developmental outcome from birth to 6 months. Neurotoxicol Teratol. 2002;24(3):283-95. https://doi.org/10.1016/s0892-0362(02)00191-5
68. Telles Mosquera J, Cote Menéndez M. Efectos toxicológicos y neuropsiquiátricos producidos por consumo de cocaína. Rev Fac Med UNAL. 2005;53(1):10-26.
69. Téllez Mosquera J. Cocaína. En: Guías para el manejo de urgencias toxicológicas. Bogotá: Ministerio de la Protección Social; 2008. p. 185-90.
70. Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, De Crescenzo F, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2015 May;2015(5):CD003352. https://doi.org/10.1002/14651858.CD003352.pub4
71. Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse. 1995 Jan;21(4):469-81.
72. Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga JA, et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. Addiction. 2007 Dec;102(12):1871-87.
73. Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder—a systematic review and meta-analysis. J Gen Intern Med. 2019;34(12):2858-73.
74. Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev. 2011 Dec;(12):CD002950. https://doi.org/10.1002/14651858.CD002950.pub3
75. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007380. https://doi.org/10.1002/14651858.CD007380.pub3
76. Indave BI, Minozzi S, Pani PP, Amato L. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2016 Mar;3:CD006306. https://doi.org/10.1002/14651858.CD006306.pub3
77. Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol. 2015;6(mar):1-13.
78. Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2015 Apr 17;(4):CD006754. https://doi.org/10.1002/14651858.CD006754.pub4
79. Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007024. https://doi.org/10.1002/14651858.CD007024.pub2
80. Pettinati HM, Kampman KM, Lynch KG, Xie H, Dackis C, Rabinowitz AR, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav. 2008 May;33(5):651-67.
81. Castells X, Kosten TR, Capellà D, Vidal X, Colom J, Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse. 2009 Jan;35(5):339-49.
82. Betancur M. C, Vicente P. B. Potencial beneficio de la N-acetilcisteína para el manejo de la adicción a pasta base de cocaína. Rev Chil Neuropsiquiatr. 2018;56(3):186-93.
83. Bremer PT, Janda KD. Conjugate vaccine immunotherapy for substance use disorder. Pharmacol Rev. 2017;69(3):298-315.
84. Programa Medellín Sana y Libre de Adicciones. Abordaje integral para la intervención de conductas adictivas. Medellín: Secretaría de Salud-Municipio de Medellín; 2015.
85. De Crescenzo F, Ciabattini M, D’Alò GL, De Giorgi R, Del Giovane C, Cassar C, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. PLoS Med. 2018;15(12):e1002715. https://doi.org/10.1371/journal.pmed.1002715
86. Agencia de Salud de Cataluña. Guía de práctica clínica sobre el tratamiento de la dependencia de la cocaína. Barcelona; 2011.



Cómo citar
Rodriguez Prada, C., Barrios Peralta, E. R., Oviedo Lugo, G., & Castellanos Garzón, R. G. (2022). Consumo de basuco: aspectos relevantes para su tratamiento. Universitas Medica, 63(1). https://doi.org/10.11144/Javeriana.umed63-1.basu
Sección
Artículos de revisión

Artículos más leídos del mismo autor/a